Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomics study of first-line irinotecan-based chemotherapy for metastatic colorectal cancer
ChiCTR-RCH-11001176Phase 4Completed
- Sponsor
- Tongji Hospital, Huazhong University of Science and Technology
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan in colorectal cancer (CRC), sponsored by Tongji Hospital, Huazhong University of Science and Technology. Primary endpoints: Incidence of neutropenia and/or leukopenia, Incidence of grade 3 to 4 diarrhea and 1 more. Started Feb 2011; status: completed.
02
Drugs
irinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR-RCH-11001176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-RCH-11001176.